VPI PATENT PORTFOLIO SUMMARY & VALUATION CONSIDERATIONS
PRIVILEGED AND CONFIDENTIAL ATTORNEY WORK PRODUCT
This memorandum is protected by the attorney-client privilege and the work product doctrine. It has been prepared by counsel in anticipation of litigation and in connection with the provision of legal advice. It is not intended for disclosure to, and should not be disclosed to, any third party without the prior written consent of Calderwood & Harkness LLP and the client.
Prepared by:
Omar Siddiqui, Lead Associate, intellectual Property Calderwood & Harkness LLP 1750 K Street NW, Suite 800 Washington, DC 20006
With the assistance of:
Christy Bauer, Working Associate, intellectual Property Calderwood & Harkness LLP
Prepared for:
Beatrice Holloway, Responsible Partner Margaret "Peggy" Ashworth, Of Counsel, National Security & CFIUS Lt. Col. (Ret.) David Caruso, Senior Counsel, Government Contracts & Export Controls
Client:
Halcyon Semiconductor Aktiengesellschaft ("HSAG")
Matter:
Acquisition of Marlowe Asset Management Photonics Inc. ("VPI") — CFIUS Filing & IP Diligence
CFIUS Case No.: CFIUS-023-07-3841
Date: August 4, 2023
Right-click to update Table of Contents
I. EXECUTIVE SUMMARY
This memorandum provides a comprehensive summary and analysis of the United States patent portfolio held by Marlowe Asset Management Photonics Inc. ("VPI") in connection with the proposed acquisition by Halcyon Semiconductor Aktiengesellschaft ("HSAG") of 100% of the outstanding equity of VPI for a base purchase price of $1.42 billion (with maximum aggregate consideration, including earnout payments, of $1.505 billion). The memorandum has been prepared as part of the intellectual property diligence workstream supporting HSAG's voluntary filing with the Committee on Foreign Investment in the United States ("CFIUS") and the negotiation of the associated National Security Agreement ("NSA").
VPI's U.S. patent portfolio consists of forty-seven (47) granted U.S. patents and twelve (12) pending U.S. patent applications. These intellectual property assets are organized into three principal patent families that correspond to VPI's core technology competencies:
1. GaN-on-SiC Epitaxial Growth Process (8 granted patents, 2 pending applications) — proprietary methods for the epitaxial growth of gallium nitride layers on silicon carbide substrates, constituting the foundation of VPI's manufacturing process.
2. HEMT Gate Structure Optimization (19 granted patents, 5 pending applications) — novel high-electron-mobility transistor gate architectures, including recessed gate designs, field-plate configurations, and passivation techniques that provide VPI's transistor-level competitive advantage.
3. mmWave Broadband Matching Network (20 granted patents, 5 pending applications) — broadband impedance matching network architectures for millimeter-wave power amplifiers, supporting both defense programs and commercial 5G infrastructure markets.
A critical finding of this analysis is that twenty-three (23) of the forty-seven (47) granted patents — representing approximately 49% of the granted portfolio — were developed in whole or in part under U.S. government-funded contracts and are therefore subject to government license rights and march-in authority under the Bayh-Dole Act (35 U.S.C. §§ 200–212) and the Defense Federal Acquisition Regulation Supplement ("DFARS") clause 252.227-7038. The U.S. government retains a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced the inventions covered by these patents for or on behalf of the United States. Additionally, the government possesses march-in rights under 35 U.S.C. § 203 and a domestic manufacturing preference under 35 U.S.C. § 204. These encumbrances are permanent, survive any change in ownership of VPI, and materially limit the exclusivity that HSAG can derive from nearly half of the portfolio.
This finding is directly relevant to the CFIUS process. The National Security Agreement currently under negotiation (NSA-2024-0019) will impose significant restrictions on the transfer of VPI's intellectual property to HSAG entities outside the United States, including cross-border R&D collaboration limitations under the Technology Control Plan ("TCP"). These restrictions, combined with the International Traffic in Arms Regulations ("ITAR") and Export Administration Regulations ("EAR") classifications applicable to VPI's products and technical data, create a "walled garden" around VPI's patent portfolio that effectively prevents HSAG from integrating VPI's patented technology into its broader global operations without navigating complex, time-consuming, and potentially outcome-uncertain regulatory approvals.
The valuation context is significant. The transaction's implied EV/Revenue multiple of approximately 4.94x (calculated as $1,420M ÷ $287.4M in FY2022 revenue) and implied EV/EBITDA multiple of approximately 23.2x ($1,420M ÷ $61.2M in FY2022 EBITDA) reflect a premium attributable in substantial part to VPI's proprietary technology position. Understanding the legal encumbrances on the IP portfolio — including government license rights, NSA-mandated transfer restrictions, and export-control limitations — is essential to assessing whether this premium is justified and to calibrating HSAG's integration planning and financial models.
Recommendation: HSAG should incorporate the government IP rights, NSA transfer restrictions, and export-control limitations identified in this memorandum into its integration planning, valuation models, and post-closing operational assumptions. The technology premium embedded in the purchase price should be evaluated against the practical constraints on HSAG's ability to realize synergistic value from VPI's patent portfolio outside of VPI's existing U.S.-based operations.
II. SCOPE AND METHODOLOGY
A. Sources Reviewed
In preparing this memorandum, we reviewed and relied upon the following materials and sources:
• VPI patent assignment records obtained from the United States Patent and Trademark Office ("USPTO"), including all recorded assignments, licenses, and security interests for each of the 47 granted patents and 12 pending applications.
• VPI's internal IP register maintained by VPI's in-house counsel (Ms. Annette Cofield), which catalogs all patents, pending applications, invention disclosures, and related metadata, including government-funding status designations.
• Government contract files for VPI's fourteen (14) active Department of Defense ("DoD") contracts, including the relevant contract clauses governing intellectual property rights (FAR 52.227-11, DFARS 252.227-7038, and related clauses), contract data rights provisions, and invention disclosure records.
• ITAR and EAR classification records maintained by VPI's export compliance office, including commodity jurisdiction determinations, USML and CCL classifications, and active export license documentation.
• Documentation relating to VPI's trade secret management program, including the trade secret registry, employee confidentiality and invention assignment agreements, and facility security protocols.
• Discussions with VPI's Vice President of Government Programs, Col. (Ret.) Bryce Hendrickson, regarding the government-funded status of specific inventions, contract performance histories, and current iEdison reporting status.
• Discussions with members of VPI's technical staff, including Dr. Nathan Trevorrow (Founder and Chief Technology Officer) and Dr. Marissa Sung-Avila (Director of GaN Process Development), regarding the technical scope and competitive significance of the patent portfolio.
• VPI's iEdison (Interagency Edison) records, confirming the reporting status of subject inventions developed under government-funded contracts.
B. Scope Limitations
This memorandum is subject to the following limitations, which should be considered when evaluating the analysis and recommendations set forth herein:
• Geographic scope. This memorandum addresses only U.S. patents and pending U.S. patent applications. VPI does not hold material foreign patent filings. VPI filed a small number of PCT applications in the 2013–2015 timeframe but elected not to enter any national phases outside the United States, consistent with VPI's predominantly U.S.-oriented customer base and the ITAR-controlled nature of its core products. Accordingly, no analysis of foreign patent portfolios has been conducted.
• No formal valuation opinion. No formal patent valuation appraisal has been commissioned in connection with this memorandum. The valuation discussion in Section XII is qualitative and strategic in nature, designed to inform HSAG's transaction team and financial advisor of the legal factors that bear on portfolio value. This memorandum does not constitute a fair-market-value opinion and should not be relied upon as such.
• No validity or enforceability opinions. We have not been asked to provide, and this memorandum does not contain, formal opinions on the validity or enforceability of any of VPI's patents. A preliminary assessment of validity risks is addressed in the companion Freedom-to-Operate memorandum prepared by Christy Bauer.
C. Coordination with Other Workstreams
This memorandum forms one component of the broader IP diligence workstream and should be read in conjunction with the following companion memoranda, each of which addresses discrete aspects of the IP-related issues arising in the proposed transaction:
1. Freedom-to-Operate / Third-Party IP Risk Memo (prepared by Christy Bauer, dated July 28, 2023) — analyzing third-party patent landscapes and identifying potential infringement risks.
2. Government Rights in Subject Inventions Memo (prepared by Omar Siddiqui, dated July 21, 2023) — providing detailed contract-by-contract analysis of government rights in VPI's subject inventions under each applicable government contract.
3. IP Transfer Restriction Analysis under the NSA (prepared by Omar Siddiqui in coordination with Peggy Ashworth, dated August 1, 2023) — analyzing the specific NSA and TCP provisions governing technology transfer between VPI and HSAG entities.
4. Trade Secret Protection Assessment (prepared by Christy Bauer, dated August 2, 2023) — evaluating VPI's trade secret management program, identifying trade secrets complementary to the patent portfolio, and assessing the adequacy of protective measures.
5. ITAR/EAR Classification Review Memorandum (prepared by Christy Bauer in coordination with David Caruso, dated July 30, 2023) — identifying VPI products and technologies requiring reclassification review post-closing and analyzing six items flagged for potential USML/CCL reclassification.
III. OVERVIEW OF VPI'S PATENT PORTFOLIO
A. Portfolio Statistics
VPI's patent portfolio comprises the following assets as of the date of this memorandum:
• Total granted U.S. patents: 47
• Total pending U.S. patent applications: 12
• Earliest priority date in portfolio: 2012 (GaN-on-SiC epitaxial growth family)
• Patent assignee of record: Marlowe Asset Management Photonics Inc. — all 47 granted patents and all 12 pending applications are assigned to VPI as reflected in the USPTO assignment records. No outstanding encumbrances, liens, or security interests were identified in the USPTO assignment records, with the exception of a UCC financing statement filed by First National Bank of New Mexico in connection with VPI's revolving credit facility, which attaches to all personal property including intellectual property. This security interest is expected to be released at closing.
VPI was incorporated on February 14, 2009, in the State of Delaware. The company was founded by Dr. Nathan Trevorrow, a former DARPA program manager who holds a Ph.D. in Electrical Engineering from Stanford University. Dr. Trevorrow is the named inventor on 28 of the 47 granted patents and continues to serve as VPI's Chief Technology Officer. His deep technical expertise and government relationships have been central to both the development and the commercial exploitation of VPI's patent portfolio. As discussed in Section XII.C below, Dr. Trevorrow's continued involvement is a critical factor in the portfolio's ongoing value.
The patents are clustered in three core technology families, each corresponding to a distinct aspect of VPI's technology stack for advanced gallium-nitride power amplifier design and manufacturing. These families are discussed in detail in Sections IV through VI of this memorandum.
B. Technology Context
VPI designs and manufactures advanced gallium-nitride (GaN) power amplifier chips used in three primary end markets: defense radar systems, satellite communications, and 5G wireless infrastructure. VPI's products are fabricated at the company's sole manufacturing facility, a 45,000-square-foot GaN-on-SiC wafer fabrication facility located at 9200 Innovation Boulevard, Albuquerque, New Mexico 87113. This facility processes 4-inch and 6-inch silicon carbide wafers using proprietary epitaxial growth and device fabrication processes protected by the patent portfolio analyzed herein.
VPI's products include items classified as defense articles under ITAR Category XI(a)(3), specifically covering electronic systems and components designed or modified for military applications. Additionally, certain of VPI's commercial-grade products are classified as dual-use items under EAR Export Control Classification Number ("ECCN") 3A001, which covers certain microwave and millimeter-wave semiconductor devices. The associated manufacturing technology falls under ECCN 3E001. These classifications have significant implications for the transferability of patent-related technical data, as discussed in Section X.
The patent portfolio provides VPI with a competitive moat in high-electron-mobility transistor ("HEMT") design and millimeter-wave power amplifier architectures. VPI's GaN HEMT devices achieve power densities and operating efficiencies that are among the highest in the industry, and the patent portfolio protects the specific design and manufacturing innovations that enable this performance. These technology advantages are the core differentiators supporting VPI's $193 million government contract backlog and its growing position in commercial 5G infrastructure markets.
C. Portfolio Distribution by Patent Family
The following table summarizes the distribution of VPI's patent portfolio across the three principal technology families:
As the table reflects, the government-funded concentration is highest in the earlier-developed families (75% in Family 1 and 63% in Family 2) and lowest in the most recent family (25% in Family 3). This distribution has meaningful implications for HSAG's post-acquisition exploitation strategy, as the non-government-funded patents offer greater operational flexibility, particularly with respect to manufacturing location and technology transfer.
IV. PATENT FAMILY 1: GaN-ON-SiC EPITAXIAL GROWTH PROCESS
A. Patent Listing and Scope
The first patent family encompasses VPI's foundational manufacturing process technology for the epitaxial growth of gallium nitride layers on silicon carbide substrates. The family consists of the following:
• Granted Patents: U.S. Patent Nos. 9,XXX,001 through 9,XXX,008 — a total of eight (8) granted patents.
• Pending Applications: Two (2) pending applications in the continuation and divisional chain extending from the original patent family.
• Earliest Priority Date: 2012.
The subject matter of this family covers proprietary methods for the epitaxial growth of GaN layers on SiC substrates, with claims directed to specific growth temperatures, buffer layer compositions (including aluminum nitride and graded aluminum gallium nitride interlayers), nucleation techniques, and defect-density control methods. Certain claims in this family are directed to the specific reactor configurations and process parameter windows that enable VPI to achieve reproducible, high-quality epitaxial films with threading dislocation densities below commercially standard thresholds.
These patents protect the fundamental manufacturing process used at VPI's Albuquerque GaN-on-SiC fab. Without the processes covered by these patents, VPI would be unable to fabricate its GaN HEMT devices to the specifications required by its defense and commercial customers. The patents thus represent the foundation upon which the remainder of the portfolio — the HEMT gate structures and the mmWave matching networks — is built.
A complete listing of the individual patents in this family, including patent numbers, issue dates, earliest priority dates, named inventors, and government-funded status, is provided in Appendix A.
B. Commercial and Strategic Significance
The GaN-on-SiC epitaxial growth process is the foundation of VPI's manufacturing capability. The company's competitive position rests in significant part on its ability to produce epitaxial wafers with superior material properties — specifically, high electron mobility, high breakdown voltage, and low defect density — compared to alternative approaches. VPI's principal competitors in the GaN power amplifier market, including Aldermere Corporation (formerly Cree), Ridgeline Partners LLC, and Penmark Corporation, rely on different substrate materials (such as GaN-on-Si) or employ different epitaxial process architectures that do not achieve the same combination of performance characteristics. VPI's process achieves industry-leading electron mobility in excess of 2,000 cm²/V·s and breakdown voltage exceeding 200 V/μm, both of which are critical performance parameters for defense-grade power amplifiers operating in harsh thermal and electromagnetic environments.
The commercial and strategic significance of this patent family is further underscored by its direct relevance to several of VPI's highest-value government contracts. The epitaxial growth process is the enabling manufacturing technology for the following programs:
• U.S. Army CERDEC GaN HEMT Modules for the AN/TPS-80 Multi-Mission Radar Program — VPI is a sole-source supplier of GaN HEMT modules for the AN/TPS-80 ground/air task oriented radar (G/ATOR) system. The contract backlog for this program stands at $52.3 million as of the most recent program review. The epitaxial process patents protect the manufacturing methodology used to produce the GaN wafers from which the AN/TPS-80 modules are fabricated.
• Missile Defense Agency GaN-Based T/R Modules for Missile Defense — VPI supplies GaN-based transmit/receive modules for a next-generation missile defense radar program. The contract backlog for this program is $38.9 million. The epitaxial growth process is essential to achieving the power handling and reliability requirements specified by MDA.
C. Government-Funded Status
Six (6) of the eight (8) granted patents in this family were developed under U.S. government-funded contracts. The relevant funding agencies are the Defense Advanced Research Projects Agency ("DARPA") and the Air Force Research Laboratory ("AFRL"). The specific contract numbers and funding sources for each government-funded patent are set forth in the contract-by-patent matrix attached as Appendix C.
As inventions developed under government-funded research, these six patents are subject to the following legal obligations and encumbrances:
Bayh-Dole Act (35 U.S.C. §§ 200–212). The Bayh-Dole Act governs the allocation of rights in inventions made under federally funded research. Under 35 U.S.C. § 202(c)(4), VPI (as the contractor) elected to retain title to the subject inventions, but the U.S. government retains a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced the inventions for or on behalf of the United States. This government license is perpetual and survives any assignment or transfer of the patents. It permits the government to have the patented inventions practiced by any third party acting on the government's behalf, including competing defense contractors.
March-in Rights (35 U.S.C. § 203). The funding agency retains march-in rights, which authorize the agency to require the contractor (or its assignee or exclusive licensee) to grant a nonexclusive, partially exclusive, or exclusive license to a responsible applicant or applicants, on reasonable terms, if the agency determines that: (a) the contractor has not achieved practical application of the subject invention within a reasonable time; (b) action is necessary to alleviate health or safety needs not reasonably satisfied by the contractor; (c) action is necessary to meet requirements for public use specified by federal regulation that are not reasonably satisfied by the contractor; or (d) the contractor has failed to comply with the U.S. manufacturing preference under § 204.
U.S. Manufacturing Preference (35 U.S.C. § 204). Products embodying subject inventions or produced through the use of subject inventions must be manufactured substantially in the United States, unless the funding agency grants a waiver upon a showing that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would manufacture substantially in the United States, or that domestic manufacture is not commercially feasible under the circumstances. This provision is directly relevant to any HSAG plans to manufacture VPI-designed components at HSAG's fabrication facilities in Germany or at other non-U.S. locations.
DFARS 252.227-7038. As DoD-funded inventions, these patents are additionally subject to the patent rights clause set forth in DFARS 252.227-7038, which imposes specific reporting obligations (including timely disclosure of subject inventions, election of title, and filing of patent applications) and provides the government with additional rights and remedies beyond those set forth in the Bayh-Dole Act.
We have confirmed with VPI management and through review of VPI's iEdison records that all reporting obligations for the subject inventions in this family are current. VPI timely disclosed each subject invention to the relevant funding agency, elected title within the prescribed timeframes, and filed patent applications as required. No delinquencies or compliance deficiencies were identified.
D. Remaining Patent Term and Maintenance
The estimated remaining patent term for the patents in this family is approximately nine (9) to eleven (11) years, based on the standard twenty-year term measured from the earliest non-provisional filing date for each patent (35 U.S.C. § 154(a)(2)). No patent term adjustments or extensions of material significance have been identified for patents in this family. The two pending continuation applications, if granted, will share the same priority date and will therefore have comparable remaining terms.
All maintenance fees for the granted patents in this family are current as of the date of this memorandum. VPI's in-house counsel (Ms. Cofield) maintains a docketing system through an outside patent annuity service (Quillon Solutions) that tracks maintenance fee due dates and ensures timely payment.
V. PATENT FAMILY 2: HEMT GATE STRUCTURE OPTIMIZATION
A. Patent Listing and Scope
The second patent family — the largest and most commercially significant in VPI's portfolio — covers VPI's proprietary high-electron-mobility transistor gate structure designs. The family consists of the following:
• Granted Patents: U.S. Patent Nos. 10,XXX,101 through 10,XXX,119 — a total of nineteen (19) granted patents.
• Pending Applications: Five (5) pending applications, including continuations, divisionals, and continuation-in-part applications.
• Earliest Priority Date: 2015.
The subject matter of this family encompasses novel HEMT gate structures, including recessed gate designs with precisely controlled recess depths and profiles, field-plate configurations (both source-connected and gate-connected field plates) that manage electric field distributions to enhance breakdown voltage, gate dielectric compositions (including Al₂O₃ and HfO₂ gate insulators deposited by atomic layer deposition), and surface passivation techniques optimized for high-power, high-frequency operation. The claims in this family span both the structural features of the transistor designs and the fabrication methods used to produce them, creating overlapping layers of protection that make design-around efforts by competitors particularly challenging.
This family represents the core of VPI's device-level intellectual property and protects the transistor architectures that are embedded in every product VPI ships, whether for defense or commercial applications. A complete listing of individual patents is provided in Appendix A.
B. Commercial and Strategic Significance
The HEMT gate structure patents protect VPI's core transistor-level designs, which provide superior power density, efficiency, and reliability compared to competing GaN HEMT architectures available from other suppliers. VPI's proprietary gate designs enable power-added efficiency (PAE) exceeding 65% at X-band frequencies and power densities above 12 W/mm at Ka-band — performance metrics that are at or near the state of the art for GaN HEMT technology and that directly translate into system-level advantages for VPI's defense and commercial customers.
These designs are incorporated in products sold across all three of VPI's primary markets: defense radar, satellite communications, and 5G infrastructure. The gate structure technology is particularly critical to the following active government programs:
• AN/TPS-80 Multi-Mission Radar Program (U.S. Army CERDEC) — $52.3 million backlog (overlapping with Family 1, as both the epitaxial growth process and the HEMT gate structures are required for the AN/TPS-80 modules).
• AFRL Next-Generation mmWave Power Amplifiers — $41.7 million backlog. This program is developing next-generation power amplifier monolithic microwave integrated circuits (MMICs) for airborne electronic warfare and communications applications, and VPI's optimized HEMT gate structures are central to meeting the program's performance specifications.
• NAVSEA Subcontract through Ironclad Defense Systems Inc. — $34.1 million backlog. VPI supplies GaN HEMT power amplifier modules to Ironclad Defense Systems Inc. under a subcontract for the U.S. Navy's surface electronic warfare improvement program. The subcontract requires VPI to manufacture modules incorporating the HEMT gate designs covered by patents in this family.
The breadth and density of the patent coverage in this family — nineteen granted patents with overlapping structural and method claims — creates a robust patent thicket that significantly raises the barrier to entry for competitors seeking to develop equivalent GaN HEMT devices. VPI's patent counsel has represented that, based on their analysis, the principal competitors' existing GaN HEMT product lines do not employ the specific gate structure innovations claimed in VPI's patents, and that design-around alternatives would likely require significant performance trade-offs.
C. Government-Funded Status
Twelve (12) of the nineteen (19) granted patents in this family were developed under government-funded contracts, representing approximately 63% of the family. The funding agencies include DARPA, AFRL, and U.S. Army Research Laboratory ("ARL"). The same Bayh-Dole license rights, march-in authority, DFARS 252.227-7038 obligations, and U.S. manufacturing preference described in Section IV.C above apply to each of these twelve patents. The specific contract-to-patent mapping is set forth in Appendix C.
The remaining seven (7) patents in this family were developed entirely with VPI's internal R&D funding and are free of government license rights. These internally funded patents are not subject to the government's paid-up license, march-in rights, or the U.S. manufacturing preference under § 204. However, they remain subject to any transfer and access restrictions imposed by the NSA and to the export-control classifications applicable to the underlying technical data, as discussed in Sections X and XI.
All iEdison reporting obligations for the government-funded patents in this family are confirmed current. No reporting delinquencies or compliance deficiencies were identified.
D. Remaining Patent Term and Maintenance
The estimated remaining patent term for the patents in this family is approximately twelve (12) to fourteen (14) years, reflecting the 2015 earliest priority date and the standard twenty-year patent term. The five pending applications, if granted, will benefit from the same priority dates and will have comparable remaining terms.
All maintenance fees for the granted patents in this family are current as of the date of this memorandum.
VI. PATENT FAMILY 3: mmWAVE BROADBAND MATCHING NETWORK
A. Patent Listing and Scope
The third patent family covers VPI's millimeter-wave broadband impedance matching network architectures. This is the newest family in the portfolio and has been the fastest-growing area of VPI's patent prosecution activity. The family consists of the following:
• Granted Patents: U.S. Patent Nos. 11,XXX,201 through 11,XXX,220 — a total of twenty (20) granted patents.
• Pending Applications: Five (5) pending applications.
• Earliest Priority Date: 2018.
The subject matter of this family encompasses broadband impedance matching network architectures for millimeter-wave power amplifiers. The claims are directed to novel transformer-based matching topologies (including integrated on-chip transformers with optimized coupling coefficients for wideband impedance transformation), distributed matching networks utilizing transmission line segments with specific impedance profiles, and integrated passive device structures that enable wideband performance at frequencies above 30 GHz. Several patents in this family claim specific combinations of matching network elements with GaN HEMT active devices (cross-referencing the transistor designs of Family 2), protecting complete amplifier circuit architectures rather than individual components.
The breadth of coverage in this family is notable: the twenty granted patents and five pending applications cover both narrow-band and broad-band matching approaches, multiple frequency ranges within the mmWave spectrum (30–100 GHz), and both single-stage and multi-stage amplifier configurations. A complete listing is provided in Appendix A.
B. Commercial and Strategic Significance
The mmWave matching network patents represent the newest and fastest-growing portion of VPI's portfolio and are the most directly relevant to VPI's expanding presence in the commercial 5G infrastructure market. The global buildout of 5G wireless networks, particularly at millimeter-wave frequencies (commonly referred to as "FR2" in the 3GPP specifications), requires high-performance, wideband power amplifiers that can operate efficiently across the 24–40 GHz frequency bands allocated for 5G service. VPI's matching network technology enables the design of power amplifiers with the wideband frequency coverage required by 5G base station equipment, and VPI's 5G product line has become a growing share of the company's revenue, contributing to VPI's $287.4 million in FY2022 revenue.
This patent family is also critical to VPI's government programs, particularly the AFRL Next-Generation mmWave Power Amplifier program ($41.7 million backlog), which requires wideband amplifier circuits operating at Ka-band and above. The matching network designs covered by this family are incorporated in the MMIC designs being developed under that program.
From a post-acquisition perspective, the 5G commercial applications of this patent family may offer the greatest value realization opportunity for HSAG. HSAG's existing semiconductor product portfolio includes RF components for wireless infrastructure, and the integration of VPI's mmWave matching network technology could enable HSAG to offer differentiated 5G power amplifier products to its global customer base. However, as discussed in Sections X and XI, the realization of these synergies is subject to NSA and export-control constraints that significantly limit HSAG's ability to transfer and exploit this technology outside of VPI's U.S. operations.
C. Government-Funded Status
Five (5) of the twenty (20) granted patents in this family were developed under government-funded contracts. The funding agencies for these five patents are AFRL and the Department of Homeland Security Science and Technology Directorate ("DHS S&T"). The Bayh-Dole Act, DFARS 252.227-7038, and U.S. manufacturing preference obligations described in Section IV.C apply to these five patents.
The remaining fifteen (15) patents were developed with VPI's internal R&D funding and are not subject to government license rights, march-in authority, or the U.S. manufacturing preference. This is the highest proportion of non-government-funded intellectual property across the three patent families, reflecting VPI's strategic decision — beginning around 2017 — to increasingly fund its mmWave matching network research from internal revenues rather than through government contracts, in order to preserve greater commercial flexibility over the resulting IP.
All iEdison reporting obligations for the five government-funded patents in this family are confirmed current.
D. Remaining Patent Term and Maintenance
The estimated remaining patent term for the patents in this family is approximately fifteen (15) to seventeen (17) years, reflecting the 2018 earliest priority date. This is the longest remaining patent life across all three families and represents the most durable patent protection in VPI's portfolio. The longevity of this protection is commercially significant because the 5G infrastructure market is still in relatively early stages of deployment, and the mmWave matching network technology is expected to remain commercially relevant throughout the remaining patent term.
All maintenance fees for the granted patents in this family are current as of the date of this memorandum.
VII. SUMMARY OF GOVERNMENT RIGHTS IN VPI PATENTS
A. Aggregate Government-Funded Patent Count
Across the entire portfolio, twenty-three (23) of VPI's forty-seven (47) granted patents — approximately 49% — were developed in whole or in part under U.S. government-funded contracts and are subject to the government intellectual property rights discussed below. The distribution by family is as follows:
• Family 1 (GaN-on-SiC Epitaxial Growth): 6 of 8 granted patents (75%)
• Family 2 (HEMT Gate Structure Optimization): 12 of 19 granted patents (63%)
• Family 3 (mmWave Broadband Matching Network): 5 of 20 granted patents (25%)
The concentration of government-funded patents in the earlier-developed families is consistent with VPI's historical reliance on government research funding during its formative years (2009–2017), when DARPA and AFRL contracts provided the primary financial support for VPI's technology development. As VPI's commercial revenue has grown — particularly in the 5G infrastructure market — the company has increasingly self-funded its R&D, resulting in a lower proportion of government-funded patents in the more recent Family 3.
B. Nature of Government Rights
The government's rights in the twenty-three government-funded patents may be summarized as follows:
Government License. Under 35 U.S.C. § 202(c)(4), the U.S. government retains a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced each subject invention for or on behalf of the United States. This license is a permanent encumbrance on the patents. It permits the government to use the patented inventions in any government program — not only the specific program that funded the invention — and to authorize any third party (including VPI's direct competitors) to practice the inventions on the government's behalf. The license does not extend to purely commercial uses by third parties, but the boundary between government and commercial use can be ambiguous in the defense-industrial context, where government contractors routinely develop commercial products derived from government-funded research.
March-in Rights. Under 35 U.S.C. § 203, the funding agency retains march-in rights that authorize the agency to require VPI (or its assignee, i.e., HSAG post-closing) to grant nonexclusive, partially exclusive, or exclusive licenses to responsible applicants, on reasonable terms, if any of the following conditions is met:
(a) The contractor or its assignee has not taken, or is not expected to take within a reasonable time, effective steps to achieve practical application of the subject invention in any field of use.
(b) Action is necessary to alleviate health or safety needs that are not reasonably satisfied by the contractor, assignee, or their licensees.
(c) Action is necessary to meet requirements for public use specified by federal regulations that are not reasonably satisfied by the contractor, assignee, or their licensees.
(d) The agreement required under 35 U.S.C. § 204 (the U.S. manufacturing preference) has not been obtained or waived, or the contractor is otherwise not complying with the manufacturing-preference requirement.
It is important to note that march-in rights have never been exercised by any federal agency since the Bayh-Dole Act was enacted in 1980. The practical risk of a march-in proceeding is therefore low. However, the risk is not zero, and it may increase in the post-acquisition context if the government perceives that HSAG — as a foreign acquirer — is not adequately commercializing the subject inventions in the United States or is diverting manufacturing activities to non-U.S. facilities. The current political environment, in which there is heightened congressional scrutiny of foreign acquisitions of critical technology companies, could further elevate this risk.
Manufacturing Preference. Under 35 U.S.C. § 204, any products embodying a subject invention or produced through the use of a subject invention must be manufactured substantially in the United States. This provision is directly relevant to HSAG's potential plans to manufacture VPI-designed components at HSAG's facilities in Germany or at other HSAG locations outside the United States. If HSAG were to shift manufacturing of products incorporating the twenty-three government-funded inventions to non-U.S. facilities without first obtaining a waiver from the relevant funding agency, HSAG could be in violation of § 204, potentially triggering the march-in rights under § 203(a)(4) discussed above. Waivers under § 204 are obtainable but require an affirmative showing to the funding agency and can take six to twelve months to process. Waiver grants are not guaranteed.
DFARS 252.227-7038. As inventions developed under DoD-funded research, the twenty-three government-funded patents are additionally subject to the patent rights provisions of DFARS 252.227-7038. This clause imposes reporting obligations, rights-retention mechanisms, and flow-down requirements specific to DoD contracts. The clause reinforces and supplements the Bayh-Dole framework and provides the government with contractual remedies in addition to the statutory remedies under the Act.
C. Implications for HSAG
The government rights described above have several significant implications for HSAG as the proposed acquirer of VPI:
No exclusivity vis-à-vis the government. HSAG cannot exclude the U.S. government from practicing the twenty-three government-funded patents. The government retains a perpetual, paid-up license that permits the government to have these inventions practiced by any contractor acting on the government's behalf. This means that, in the defense market, VPI's competitors could potentially manufacture products incorporating VPI's patented inventions if they are doing so under government contract, without owing royalties to VPI or HSAG.
March-in risk. Although historically unexercised, march-in rights create a theoretical risk that the government could compel licensing of VPI's patents to competing contractors. This risk, while low, would increase if HSAG were perceived as not adequately commercializing the technology within the United States or as moving manufacturing offshore in a manner inconsistent with § 204. HSAG should be attentive to this risk and should ensure that its post-acquisition integration plans can withstand government scrutiny on these points.
Manufacturing location constraints. The U.S. manufacturing preference under § 204 constrains HSAG's ability to realize cost efficiencies by relocating production of government-funded-invention-embodying products to HSAG's German or other non-U.S. fabrication facilities. Products incorporating these inventions must continue to be manufactured substantially in the United States — effectively tethering these product lines to VPI's Albuquerque facility or other U.S.-based manufacturing operations.
Reporting continuity. All twenty-three government-funded patents are properly reported in VPI's iEdison records, and no delinquencies have been identified. HSAG must ensure the continuity of these reporting obligations post-closing, as failure to comply with iEdison reporting requirements could jeopardize VPI's title to the subject inventions.
VIII. PENDING PATENT APPLICATIONS
A. Summary. VPI has twelve (12) pending U.S. patent applications, distributed across the three patent families as follows:
• Family 1 (GaN-on-SiC Epitaxial Growth): 2 pending applications
• Family 2 (HEMT Gate Structure Optimization): 5 pending applications
• Family 3 (mmWave Broadband Matching Network): 5 pending applications
All twelve applications are assigned to VPI as reflected in the USPTO records. The applications are at various stages of prosecution before the USPTO, ranging from recently filed applications that have not yet received a first office action to applications with pending non-final office actions requiring response. Several of the applications are continuations or divisionals of granted patents within their respective families, extending patent coverage to specific embodiments, design variations, and method variants that were disclosed but not claimed in the parent patents.
A complete listing of the pending applications, including application numbers, filing dates, current prosecution status, and government-funded status, is provided in Appendix B.
B. Prosecution Status and Risks
As of the date of this memorandum, no pending applications have received final rejections from the USPTO. The prosecution posture of the portfolio is generally favorable, though certain applications warrant monitoring:
• Three (3) applications in Family 2 (HEMT Gate Structure Optimization) have received non-final office actions containing prior art rejections under 35 U.S.C. §§ 102 and/or 103. The examiner has cited a combination of academic publications and third-party patent references as prior art. VPI's outside patent counsel (Fogarty & Chen LLP) is currently preparing responses to these office actions, which are due within the standard three-month response period (extendable to six months with payment of extension fees). Based on our review of the cited prior art and the available claim amendment strategies, we assess the likelihood of obtaining allowance for at least a subset of the pending claims as moderate to high. The independent claims may require narrowing amendments to distinguish over the cited references, but the specification as filed supports amended claims of meaningful scope.
• The remaining nine (9) applications are either awaiting first office actions or have recently been filed and are in the pre-examination queue. No significant prosecution risks have been identified for these applications at this stage.
If all twelve pending applications are ultimately granted, VPI's total patent portfolio would expand to fifty-nine (59) patents, further strengthening the company's intellectual property position across all three technology families.
C. Government-Funded Status of Pending Applications
At least four (4) of the twelve (12) pending applications relate to inventions developed under government-funded contracts. These four applications are continuations or divisionals of granted patents that are themselves government-funded, and the subject inventions were disclosed and reported through VPI's iEdison filings in connection with the parent patent applications. If these four applications are granted, the resulting patents will carry the same Bayh-Dole Act and DFARS 252.227-7038 encumbrances as the related parent patents, including the government's paid-up license, march-in rights, and the U.S. manufacturing preference.
The remaining eight (8) pending applications relate to inventions developed with VPI's internal R&D funding and are not expected to carry government IP rights encumbrances.
IX. TRADE SECRET COMPLEMENT TO PATENT PORTFOLIO
While a comprehensive analysis of VPI's trade secrets is provided in the separate Trade Secret Protection Assessment memorandum prepared by Christy Bauer, a brief summary is warranted here to place the patent portfolio in its full competitive context.
VPI maintains a formal trade secret management program under which the company has identified and registered thirty-one (31) internal trade secrets. These trade secrets are cataloged in a controlled registry maintained by VPI's in-house counsel and are subject to access controls, employee confidentiality and invention assignment agreements, and physical and cybersecurity protections commensurate with their sensitivity.
The registered trade secrets primarily relate to two categories of proprietary information:
• Proprietary GaN epitaxial growth recipes: Specific combinations of process parameters — including precursor gas flow rates, chamber pressures, substrate temperatures during nucleation and growth phases, and doping profiles — that VPI's process engineers have optimized through years of iterative experimentation. These recipes represent the practical know-how required to implement the epitaxial growth processes that are claimed at a higher level of abstraction in the Family 1 patents. The recipes contain a level of process detail that is not disclosed in the patent filings and that would be extremely difficult for a competitor to reverse-engineer from finished wafers.
• Die-level reliability screening processes: Proprietary test protocols and acceptance criteria used by VPI to screen individual GaN HEMT die for reliability defects prior to packaging and delivery. These screening processes are critical to achieving the high reliability standards required by defense customers and are considered among VPI's most closely guarded competitive advantages.
The trade secrets are complementary to, but not coextensive with, the patent portfolio. The patents protect the broader inventive concepts (e.g., the use of a particular buffer layer composition or gate structure geometry), while the trade secrets protect the detailed process know-how required to implement those concepts at production scale with commercially acceptable yield and reliability. Together, the patent and trade secret portfolios constitute VPI's core intellectual property moat. Any assessment of the value of VPI's intellectual property — whether for purposes of this transaction or otherwise — should consider both layers of protection together, recognizing that the practical competitive advantage derived from VPI's technology rests on the combination of disclosed (patented) and undisclosed (trade secret) knowledge.
X. EXPORT CONTROL CLASSIFICATIONS AFFECTING IP TRANSFER
The transferability of VPI's patent-related technical data to HSAG personnel is significantly constrained by the export-control classifications applicable to VPI's products and technology. This section summarizes the key classifications and their practical implications. A more detailed treatment is provided in the ITAR/EAR Classification Review Memorandum prepared by Christy Bauer in coordination with David Caruso.
VPI's products and related technical data are classified under the following regimes:
• ITAR Category XI(a)(3): Certain of VPI's GaN HEMT power amplifier modules designed for military radar and electronic warfare applications are classified as defense articles on the U.S. Munitions List ("USML") under Category XI(a)(3), which covers electronic equipment and components specifically designed or modified for military applications. Technical data directly related to these defense articles is controlled under ITAR Category XI(e) as defense services or technical data.
• EAR ECCN 3A001: VPI's commercial-grade and dual-use GaN HEMT devices are classified under Commerce Control List ("CCL") ECCN 3A001, covering certain types of microwave and millimeter-wave semiconductor devices and integrated circuits. This classification subjects these items to licensing requirements for export to most destinations.
• EAR ECCN 3A991: Certain of VPI's lower-specification commercial products are classified under ECCN 3A991.
• EAR ECCN 3E001: The manufacturing technology and design information associated with VPI's ECCN 3A001 and 3A991 products is classified under ECCN 3E001, which controls technology required for the development or production of items controlled under 3A001. This classification is particularly significant because it applies to the technical data underlying VPI's patents — including design specifications, process parameters, and engineering drawings — and subjects the transfer of such information to non-U.S. persons to EAR licensing requirements.
VPI has been registered with the Directorate of Defense Trade Controls ("DDTC") since 2011 (Registration No. M-24817) and maintains an active export compliance program overseen by its export compliance officer. VPI currently holds three (3) active DSP-5 export licenses authorizing specific product shipments to NATO ally customers in the United Kingdom and Australia. These licenses cover the export of finished defense articles and do not authorize the transfer of patent-related technical data or manufacturing technology to HSAG or its personnel.
The practical implication of these export-control classifications is significant for HSAG's post-acquisition plans. The transfer of technical data — including patent-related design information, manufacturing specifications, process know-how, and any information derived from VPI's patented inventions — to non-U.S. persons constitutes an export or deemed export requiring prior authorization under ITAR or EAR, as applicable. HSAG personnel who are German nationals (or nationals of any country other than the United States) are "foreign persons" for purposes of both ITAR and EAR. Accordingly, any sharing of VPI's controlled technical data with HSAG's German R&D teams, executives, or other non-U.S. personnel would require the prior issuance of specific export licenses or the applicability of a statutory or regulatory license exemption.
This constraint significantly limits the synergistic value of VPI's patent portfolio to HSAG's global operations. While HSAG will own VPI — and by extension, all 47 patents and 12 pending applications — post-closing, the export-control framework prevents HSAG from freely transferring the technical substance of those patents to its non-U.S. operations. In effect, the patents' commercial utility to HSAG is largely confined to VPI's existing U.S.-based operations, at least absent the successful procurement of specific export authorizations.
The ITAR/EAR Classification Review Memorandum prepared by Christy Bauer identifies six (6) VPI items that warrant reclassification review post-closing, as changes in product specifications or end-use applications may affect their current USML or CCL classifications. HSAG should address these reclassification issues as part of its post-closing integration activities, in coordination with David Caruso and VPI's export compliance team.
XI. NSA RESTRICTIONS ON IP TRANSFER AND EXPLOITATION
A. Technology Control Plan (TCP) Obligations
Under the National Security Agreement (NSA-2024-0019) as currently negotiated between HSAG, VPI, and the U.S. government (acting through CFIUS and the Department of Defense as the lead monitoring agency), HSAG and VPI will be required to implement and maintain a Technology Control Plan ("TCP") that governs the handling, storage, and transfer of VPI's controlled technical data. The TCP will impose the following principal obligations relevant to VPI's patent portfolio:
• Prohibition on unauthorized transfer. The TCP will prohibit the transfer of VPI technical data that is controlled under ITAR or EAR to any non-U.S. person — including HSAG personnel — without prior authorization from the U.S. government. This prohibition extends to patent-related technical data, engineering drawings, manufacturing process specifications, and any technical information derived from or related to VPI's patented inventions.
• Data segregation. The TCP will require that all controlled technical data be maintained exclusively on VPI's IT systems, which must be physically and logically separated from HSAG's corporate IT infrastructure. No shared cloud infrastructure, shared servers, or shared data storage systems are permitted between VPI and HSAG IT environments. This data segregation requirement ensures that HSAG personnel outside the United States cannot inadvertently or intentionally access VPI's controlled patent-related information through shared IT systems.
• Access controls. The TCP will require VPI to maintain access logs and audit trails documenting all access to controlled technical data, and to restrict access to authorized U.S.-person employees with appropriate security clearances and need-to-know authorization.
B. Facility and Personnel Access Restrictions
The NSA imposes additional restrictions on physical access to VPI's facilities and on the roles of HSAG-designated personnel in VPI's governance:
• Facility access. HSAG personnel may not access VPI's classified facilities — specifically, the Albuquerque fabrication facility's clean room Sections C-7 through C-12, where classified and ITAR-controlled manufacturing operations are conducted — without prior approval from the Defense Counterintelligence and Security Agency ("DCSA") and VPI's Government Security Committee ("GSC"). In practice, such approvals are rarely granted for non-U.S.-citizen personnel and would require the individual to hold or be eligible for the requisite security clearance.
• Government Security Committee. The NSA requires VPI to establish and maintain a Government Security Committee composed of three (3) U.S.-citizen Security Board Members, each of whom must hold or be eligible for a Top Secret / Sensitive Compartmented Information (TS/SCI) security clearance. The GSC will have exclusive authority over all classified and ITAR-controlled programs, including the authority to approve or deny access to classified information, oversee compliance with the TCP, and ensure that VPI's government contract obligations are fulfilled without interference from HSAG.
• HSAG board representation. HSAG will be permitted to designate two (2) members of VPI's board of directors. However, these HSAG-designated directors may not hold or access classified information, may not participate in GSC deliberations, and may not receive VPI technical data that is controlled under ITAR or EAR. Their role will be limited to general corporate governance, financial oversight, and strategic direction for VPI's non-controlled commercial activities.
C. Practical Impact on Patent Exploitation